Ainos, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $8.9M
- Price
- $1.21
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.11%
- Volume
- 60.8K
About
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
Quick stats
Shares outstanding7.4M
Computed float2.1M
Float / shares28.4%
Cash runway (months)0.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001014763
Websitehttps://www.ainos.com
AI Summary
AI-generated1/33
minorbullishoperations update
Ainos Completes VELDONA Technology Transfer, Triggering $600,000 License Payment
Ainos completed the required data delivery and technology transfer under its VELDONA license agreement, with the licensing partner confirming completion in writing on September 29.
The completion triggers a $600,000 initial license payment due within 15 business days, part of a previously announced potential $10 million licensing framework that includes conditional payments tied to a first sublicense and 15 additional indications.
Ainos is also entitled to 25% of net sublicensing revenue; the milestone follows delivery of 1,400 AI Nose systems to ASE and marks continued execution of the company's licensing and commercialization agenda.
Red flags
- company expects net losses for the foreseeable future and may need additional capital
- conditional payments and license fee receipt remain subject to uncertainty per forward-looking statements